Hubei Hongyuan Pharmaceutical Co., Ltd.

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is located in Luotian County at the southern foot of the Dabie Mountains. Founded in 2002, the company has a registered capital of 350 million yuan, total assets of 1.8 billion yuan, and covers an area of 600,000 square meters. It achieves annual sales revenue of 1.6 billion yuan and earns 48 million US dollars in foreign exchange through exports. It has 5 wholly-owned subsidiaries and 2 equity-participating companies, with over 2,000 employees in total, including more than 200 project R&D personnel.
Through unremitting efforts, the company has formed an industrial layout of 7 series and more than 50 varieties, including pharmaceuticals, food and feed additives, new energy, polymer materials, and pharmaceutical intermediates. Among them, 5 varieties are listed in the National High-tech Product Catalog. Its main products, metronidazole, glyoxal, and honeysuckle herbal tea, have been rated as "Hubei Province Famous Brand Products." The technology, scale, and quality of the company's main products—metronidazole, glyoxal, and glyoxylic acid—hold a leading position internationally.
On November 4, 2014, the company was listed on the National Equities Exchange and Quotations system, with the securities abbreviation: Hongyuan Pharmaceutical, and securities code: 831265. It is currently preparing for a main board listing.
On March 1, 2020, the company invested in and constructed a new production base in Wuxue, mainly focused on API intermediates, polymer materials, and fluorochemical products. The total investment of the project is 1.53 billion yuan, with a planned land area of 700 mu. After the project is completed, it can achieve annual sales revenue of 2.5 billion yuan and provide employment for more than 1,000 people.
Hongyuan Company's Wuhan R&D Center is located in the Biomedical Park, No. 388 Gaoxin 2nd Road, East Lake High-tech Development Zone, Wuhan City, covering an area of 1,200 square meters. It is mainly engaged in the research and development of chemical drugs, traditional Chinese medicines, traditional Chinese medicine formula granules, and health products. There are currently 30 personnel, of whom over 70% hold master's degrees, 3 have senior professional titles, and 12 have intermediate professional titles. Ongoing projects include: consistency evaluation of generic drugs, generic drug development, new traditional Chinese medicine research and formula granule research, and health product research. The R&D center is equipped with well-appointed pharmaceutical R&D equipment, including synthesis, analysis, formulation, and traditional Chinese medicine extraction equipment. This includes dry granulators, wet granulators, tablet presses, capsule filling machines, WATERS, Agilent, and Shimadzu liquid chromatographs, gas chromatographs, automatic dissolution testers, infrared spectrometers, precision analytical balances, stability test chambers, multi-functional traditional Chinese medicine extraction units, large rotary evaporators, high-low temperature circulating devices, and other pilot-scale equipment. The R&D center is equipped with 21 large-scale ventilation facilities.
Now, in light of the company's situation, we are widely recruiting professionals and technical talents in various fields.